Update on the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine
Lung Cancer remains a major cause of death in of both women and men in our society. Lung cancer treatment paradigms have changed enormously as we’ve started to understand the genetic complexity and the multiple driver mutations influencing the disease. Therapeutics directed towards, or to inhibit si...
Saved in:
Superior document: | Frontiers Research Topics |
---|---|
: | |
Year of Publication: | 2018 |
Language: | English |
Series: | Frontiers Research Topics
|
Physical Description: | 1 electronic resource (95 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993544445904498 |
---|---|
ctrlnum |
(CKB)4920000000094350 (oapen)https://directory.doabooks.org/handle/20.500.12854/61730 (EXLCZ)994920000000094350 |
collection |
bib_alma |
record_format |
marc |
spelling |
Barbara Melosky auth Update on the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine Update on the Treatment of Metastatic Non-small Cell Lung Cancer Frontiers Media SA 2018 1 electronic resource (95 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Frontiers Research Topics Lung Cancer remains a major cause of death in of both women and men in our society. Lung cancer treatment paradigms have changed enormously as we’ve started to understand the genetic complexity and the multiple driver mutations influencing the disease. Therapeutics directed towards, or to inhibit signaling pathways has resulted in increased life spans for our patients. Over the last two decades, we have gone from simple chemotherapy used to treat all, to a personalized medicine approach for the majority. For non-small cell lung cancer patients without driver mutations, the world of immune oncology has arrived. These improved long-term outcomes mean that now our lung cancer patients can live with their cancers, but without progression. The aim of this book is to catalogue the current state of knowledge for the many facets of advanced lung cancer. It describes current treatment approaches for driver mutations, rare mutations, and rare thoracic malignancies such as neuroendocrine tumors. Most importantly, this book addresses the topics of palliative treatment and care which allow our patients to enjoy longer survival with the highest quality of life. We hope you enjoy this e-book. The future is brighter for lung cancer patients and as lung cancer specialists; we finally feel sense optimism about treatment options for our patients. English Updates on Diagnoses and Treatments Metastatic NSCLC 2-88945-397-9 Vera Hirsh auth |
language |
English |
format |
eBook |
author |
Barbara Melosky |
spellingShingle |
Barbara Melosky Update on the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine Frontiers Research Topics |
author_facet |
Barbara Melosky Vera Hirsh |
author_variant |
b m bm |
author2 |
Vera Hirsh |
author2_variant |
v h vh |
author_sort |
Barbara Melosky |
title |
Update on the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine |
title_full |
Update on the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine |
title_fullStr |
Update on the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine |
title_full_unstemmed |
Update on the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine |
title_auth |
Update on the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine |
title_alt |
Update on the Treatment of Metastatic Non-small Cell Lung Cancer |
title_new |
Update on the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine |
title_sort |
update on the treatment of metastatic non-small cell lung cancer (nsclc) in new era of personalised medicine |
series |
Frontiers Research Topics |
series2 |
Frontiers Research Topics |
publisher |
Frontiers Media SA |
publishDate |
2018 |
physical |
1 electronic resource (95 p.) |
isbn |
2-88945-397-9 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT barbaramelosky updateonthetreatmentofmetastaticnonsmallcelllungcancernsclcinneweraofpersonalisedmedicine AT verahirsh updateonthetreatmentofmetastaticnonsmallcelllungcancernsclcinneweraofpersonalisedmedicine AT barbaramelosky updateonthetreatmentofmetastaticnonsmallcelllungcancer AT verahirsh updateonthetreatmentofmetastaticnonsmallcelllungcancer |
status_str |
n |
ids_txt_mv |
(CKB)4920000000094350 (oapen)https://directory.doabooks.org/handle/20.500.12854/61730 (EXLCZ)994920000000094350 |
carrierType_str_mv |
cr |
hierarchy_parent_title |
Frontiers Research Topics |
is_hierarchy_title |
Update on the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine |
container_title |
Frontiers Research Topics |
author2_original_writing_str_mv |
noLinkedField |
_version_ |
1787548743235534848 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02399nam-a2200313z--4500</leader><controlfield tag="001">993544445904498</controlfield><controlfield tag="005">20231214132839.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202102s2018 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)4920000000094350</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/61730</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)994920000000094350</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Barbara Melosky</subfield><subfield code="4">auth</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Update on the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine</subfield></datafield><datafield tag="246" ind1=" " ind2=" "><subfield code="a">Update on the Treatment of Metastatic Non-small Cell Lung Cancer </subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">Frontiers Media SA</subfield><subfield code="c">2018</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (95 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Frontiers Research Topics</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Lung Cancer remains a major cause of death in of both women and men in our society. Lung cancer treatment paradigms have changed enormously as we’ve started to understand the genetic complexity and the multiple driver mutations influencing the disease. Therapeutics directed towards, or to inhibit signaling pathways has resulted in increased life spans for our patients. Over the last two decades, we have gone from simple chemotherapy used to treat all, to a personalized medicine approach for the majority. For non-small cell lung cancer patients without driver mutations, the world of immune oncology has arrived. These improved long-term outcomes mean that now our lung cancer patients can live with their cancers, but without progression. The aim of this book is to catalogue the current state of knowledge for the many facets of advanced lung cancer. It describes current treatment approaches for driver mutations, rare mutations, and rare thoracic malignancies such as neuroendocrine tumors. Most importantly, this book addresses the topics of palliative treatment and care which allow our patients to enjoy longer survival with the highest quality of life. We hope you enjoy this e-book. The future is brighter for lung cancer patients and as lung cancer specialists; we finally feel sense optimism about treatment options for our patients.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Updates on Diagnoses and Treatments</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Metastatic NSCLC</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">2-88945-397-9</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vera Hirsh</subfield><subfield code="4">auth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:33:42 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2019-11-10 04:18:40 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5337646360004498&Force_direct=true</subfield><subfield code="Z">5337646360004498</subfield><subfield code="b">Available</subfield><subfield code="8">5337646360004498</subfield></datafield></record></collection> |